South & Central America Human Microbiome Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The human microbiome market in South and Central America is projected to grow significantly, reaching approximately USD 147.22 million by 2031, up from USD 39.65 million in 2023, with an impressive compound annual growth rate (CAGR) of 17.8% during this period.

Executive Summary and Market Analysis

The market is divided into key regions: Brazil, Argentina, and the Rest of South and Central America. The growth of the human microbiome market in this region is supported by well-established healthcare systems, increased government support, and a rise in research and development activities. Additionally, the rising incidence of chronic diseases and the adoption of unhealthy lifestyles are expected to drive demand for microbiome-related products and services.

Market Segmentation

The South and Central America human microbiome market can be segmented based on type, application, and disease type:

Type: The market is categorized into products and software/services, with products dominating the market share in 2023. The product segment includes probiotics and prebiotics.
Application: The market is further divided into therapeutics, diagnostics, and research, with therapeutics holding the largest market share in 2023.
Disease Type: The market is segmented into obesity, diabetes, autoimmune disorders, cancer, gastrointestinal (GIT) issues, and others, with GIT issues leading the market in 2023.

Market Outlook

The human microbiome's potential to revolutionize healthcare has led to increased investments in research and development. The microbiome, consisting of trillions of microorganisms, plays a crucial role in maintaining health and preventing diseases. Biotech startups and pharmaceutical companies are heavily investing in microbiome-based therapies. For instance, Xome Life Sciences, a pioneering microbiome startup in India, is developing diagnostic and therapeutic tools aimed at improving health outcomes.

A notable example of microbiome innovation is the FDA-approved treatment by Seres Therapeutics for recurrent Clostridium difficile infections, showcasing the therapeutic potential of microbiome-based drugs. Companies like Vedanta Biosciences are also raising significant funds to develop immunotherapies derived from microbiomes for conditions such as autoimmune disorders and cancer. Investors like Seventure Partners and Flagship Pioneering are increasingly funding microbiome data analysis companies, highlighting the growing recognition of the microbiome's importance in health. This surge in investment is expected to drive advancements in precision medicine and therapeutic solutions, creating numerous opportunities in the market.

Country Insights

The South and Central America human microbiome market is primarily composed of Brazil, Argentina, and other countries in the region, with Brazil holding the largest market share in 2023. A recent study published in the Brazilian Journal of Infectious Diseases highlighted the analysis of the sputum microbiome in cystic fibrosis patients, revealing a high presence of Burkholderia cepacia complex (Bcc). This research could lead to improved diagnostic methods and treatments for chronic diseases, thereby increasing the demand for microbiome solutions in Brazil.

Pharmaceutical companies and biotech startups are actively investing in innovative microbiome therapeutics, leading to the development of new products. For example, in April 2023, Nintx, a startup based in Sao Paulo, Brazil, collaborated with federal institutions and private companies to create new drugs from plant-based natural products, receiving a USD 3 million investment from Pitanga venture capital in 2022 to accelerate their market entry. This trend of increasing research and investment is propelling the growth of the human microbiome market in Brazil.

Company Profiles

Key players in the human microbiome market include MaaT Pharma, Ferring Holdings SA, AOBiome Therapeutics Inc, Finch Therapeutics Group Inc, Seres Therapeutics Inc, Merck & Co Inc, Rebiotix, Inc., Yakult Honsha Co., Ltd., IFF Nutrition & Biosciences, and Synthetic Biologics, Inc. These companies are employing various strategies such as market expansion, product innovation, and mergers and acquisitions to enhance their offerings and increase their market presence.

Product Code: BMIRE00032120

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. South & Central America Human Microbiome Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Significant Investments by Key Market Players
- 4.1.2 Government Initiatives
4.2 Market Restraints
- 4.2.1 Challenges During Production of Microbiome
4.3 Market Opportunities
- 4.3.1 Robust Investment in Research and Development
4.4 Future Trends
- 4.4.1 Emergence of Precision Medicine
4.5 Impact of Drivers and Restraints:

5. Human Microbiome Market - South & Central America Analysis

5.1 South & Central America Human Microbiome Market Revenue (US$ Million), 2021-2031
5.2 South & Central America Human Microbiome Market Forecast Analysis

6. South & Central America Human Microbiome Market Analysis - by Type

6.1 Product
- 6.1.1 Overview
- 6.1.2 Product: South & Central America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.2 Software and Services
- 6.2.1 Overview
- 6.2.2 Software and Services: South & Central America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. South & Central America Human Microbiome Market Analysis - by Application

7.1 Therapeutics
- 7.1.1 Overview
- 7.1.2 Therapeutics: South & Central America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Diagnostics
- 7.2.1 Overview
- 7.2.2 Diagnostics: South & Central America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Research
- 7.3.1 Overview
- 7.3.2 Research: South & Central America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. South & Central America Human Microbiome Market Analysis - by Disease Type

8.1 Obesity
- 8.1.1 Overview
- 8.1.2 Obesity: South & Central America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Diabetes
- 8.2.1 Overview
- 8.2.2 Diabetes: South & Central America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Autoimmune Disorder
- 8.3.1 Overview
- 8.3.2 Autoimmune Disorder: South & Central America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Cancer
- 8.4.1 Overview
- 8.4.2 Cancer: South & Central America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.5 GIT
- 8.5.1 Overview
- 8.5.2 GIT: South & Central America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: South & Central America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. South & Central America Human Microbiome Market - Country Analysis

9.1 South & Central America
- 9.1.1 South & Central America Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.1 South & Central America Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.2 Brazil: South & Central America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.1.2.1 Brazil: South & Central America Human Microbiome Market Share - by Type
    - 9.1.1.2.2 Brazil: South & Central America Human Microbiome Market Share - by Product
    - 9.1.1.2.3 Brazil: South & Central America Human Microbiome Market Share - by Application
    - 9.1.1.2.4 Brazil: South & Central America Human Microbiome Market Share - by Disease Type
  - 9.1.1.3 Argentina: South & Central America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.1.3.1 Argentina: South & Central America Human Microbiome Market Share - by Type
    - 9.1.1.3.2 Argentina: South & Central America Human Microbiome Market Share - by Product
    - 9.1.1.3.3 Argentina: South & Central America Human Microbiome Market Share - by Application
    - 9.1.1.3.4 Argentina: South & Central America Human Microbiome Market Share - by Disease Type
  - 9.1.1.4 Rest of South & Central America: South & Central America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.1.4.1 Rest of South & Central America: South & Central America Human Microbiome Market Share - by Type
    - 9.1.1.4.2 Rest of South & Central America: South & Central America Human Microbiome Market Share - by Product
    - 9.1.1.4.3 Rest of South & Central America: South & Central America Human Microbiome Market Share - by Application
    - 9.1.1.4.4 Rest of South & Central America: South & Central America Human Microbiome Market Share - by Disease Type

10. Competitive Landscape

10.1 Heat Map Analysis by Key Players
10.2 Company Positioning and Concentration

11. Industry Landscape

11.1 Overview
11.2 Growth Strategies in the Human Microbiome Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 MaaT Pharma
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Ferring Holdings SA
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 AOBiome Therapeutics Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Finch Therapeutics Group Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Financial Overview
- 12.4.4 SWOT Analysis
- 12.4.5 Key Developments
12.5 Seres Therapeutics Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Merck & Co Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Yakult Honsha Co., Ltd.
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Rebiotix, Inc.
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 IFF Nutrition & Biosciences
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Synthetic Biologics, Inc.
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About Us
13.2 List of Abbreviations